F. Erdkamp

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

C.J.A. Punt, J. Tol, C. J. Rodenburg et al. · Journal of Clinical Oncology · 2008 · 130 citations

Medicine, Oncology, Pharmacology +16

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Medicine, Oncology, Pharmacology +16

Sclerosing peritonitis: an unusual cause of ascites in a patient with systemic lupus erythematosus.

Manon J. Pepels, Fabrice Péters, Joseph Mebis et al. · PubMed · 2006 · 30 citations

Life Sciences, Immunology, Pathology +7

Abstract S1-03: First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

VC Tjan-Heijnen, IE van Hellemond, P.G.M. Peer et al. · Cancer Research · 2017 · 30 citations

Medicine, Oncology, Pharmacology +15